TREM2+ LAMs not only promote tumor angiogenesis by facilitating VEGF signaling, but also promote cancer progression by suppressing anti-tumor immune responses, correlating with poor clinical outcomes in HCC patients (18) (Figure 4B). The gene discussed is TREM2; the disease is hepatocellular carcinoma.